Gewinn- und Verlustrechnung von Guardant Health, Inc.

ISCB offers ultra-low costs and 1,500+ holdings for diversification, while BBSC concentrates on fewer names with higher recent returns.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and mortality for younger adults as the leading cause of cancer death for those under 50.3 Shield is the first and onl.

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offering unique advantages for investors.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Not intended for distribution to U.S. newswire services or for dissemination in the U.S. Red Deer, Alberta--(Newsfile Corp. - June 15, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that the Court of King's Bench of Alberta has granted the final order authorizing Gamehost to proceed with its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the shareholders of Gamehost (the "Gamehost Shareholders") held on June 11, 2026.

Red Deer, Alberta--(Newsfile Corp. - June 12, 2026) - Gamehost Inc. (TSX: GH) ("Gamehost") announced that its shareholders (the "Gamehost Shareholders") have approved its previously announced transaction with Pure Casino Entertainment Limited Partnership ("Pure") pursuant to which a subsidiary of Pure will acquire all of the outstanding common shares of Gamehost (the "Gamehost Shares") for $13.65 in cash per share (the "Transaction"). The Transaction was approved at a special meeting of the Gamehost Shareholders held on June 11, 2026 (the "Meeting").

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test tha.

This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace negotiations and would block the Strait of Hormuz. But that sell-off lasted until about noon, before a big reversal, which, by that... Here Are Tuesday's Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts,